Recent

% | $
Quotes you view appear here for quick access.

TD Ameritrade Holding Corporation Message Board

news_to_use 21 posts  |  Last Activity: Jul 6, 2016 3:48 PM Member since: Jan 26, 1999
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • This happens in every stock that I buy - I constantly warn the shorts that they are going to be rolled over and lose their shirts. Then it happens. I can't feel sorry for you greedy shortsellers (or longs who sold at the bottom when I told them I was buying). You day traders better enjoy your last days, since Hillary is going to put a fee on each transaction to pay for her free college for everyone plan. Hope some of you shorts lose it all.

  • news_to_use news_to_use Jul 1, 2016 4:06 PM Flag

    You better check that figure. They paid just under a half billion Dendreon, the maker of the prostate cancer treatment Provenge, has been sold for $495 million to Valeant Pharmaceuticals International. The Wall Street Journal reports that the purchase price increased by $95 million last Thursday, with Valeant picking up $80 million of Dendreon’s cash as well as an experimental drug known as D-3263.

    Valeant, which said in a press release that the deal will officially close today, also indicated that it will retain Dendreon’s employees and supply contracts.

  • Reply to

    Stifel reiterates $55 target on VRX

    by equityvaluation Jul 1, 2016 10:13 AM
    news_to_use news_to_use Jul 1, 2016 3:33 PM Flag

    They are right that $55 is a realistic target. I came up with $45 using very, very conservative estimates and some fire sale prices on non-core assets. I want to thank everyone who sold their shares to me today, bought another 20,000. Thank you.

  • news_to_use news_to_use Jun 29, 2016 6:31 PM Flag

    The key to negotiating is to take your time. The first one who speaks loses. This company does not have to sell anything - yes, that is not a typo - they do not have to sell anything, despite what the analysts and pundits state. They may sell some assets to give themselves a margin of safety, but they do not need to sell any in the near future. The stock price may have been driven down here by the acquiring company through shorting to create a climate of urgency (this is my belief as it is often used in large negotiations also), but current stock price is meaningless to true investors as they know what a company is worth. Management is doing the right thing in taking their time. Would you prefer they signed something last Friday in the heat of the Brexit meltdown?

  • Reply to

    B&L worth $20 billion

    by uniowner Jun 29, 2016 5:31 PM
    news_to_use news_to_use Jun 29, 2016 6:13 PM Flag

    We think B&L will sell for around $11.5 Billion. That's still 53% more than Crooked Cramer states. (It's no wonder that he supports Crooked Hillary)

  • news_to_use news_to_use Jun 28, 2016 10:53 PM Flag

    sorry, that should e $12.5 Billion.

  • news_to_use news_to_use Jun 28, 2016 10:53 PM Flag

    I should note that Google paid $121.5 billion just to buy only the patents of Motorola Mobility and all of that went to goodwill.

  • news_to_use news_to_use Jun 28, 2016 10:49 PM Flag

    It appears that you don't understand what goodwill is. You cannot determine if a company overpaid for acquisitions by looking at goodwill. Many intangibles are included in goodwill such as value of patents and future projected cash flow. Most large specialty pharmas carry heavy goodwill because they are buying intangibles patents and projections. AGN for example has over $46 billion in goodwill, as compared to $18 billion here. If you are short because of goodwill, I suggest you cover.

  • news_to_use news_to_use Jun 28, 2016 4:24 PM Flag

    This is correct and yes it includes their line of credit money. Despite what the shorts and some analysts say, they really don't need to sell any assets now. They are in talks with several companies so they will only sell if they get the right price. The stock price dropped over total nonsense the last 2 days.

  • news_to_use by news_to_use Jun 28, 2016 4:13 PM Flag

    They are in talks right now. You are a dumb #$%$. You don't rush these things.

  • news_to_use by news_to_use Jun 27, 2016 7:54 PM Flag

    Friday, 27 May 2016 | 6:25 AM ET
    Reuters
    COMMENTSStart the Discussion
    Valeant Pharmaceuticals received a joint takeover offer from Japan's Takeda Pharmaceutical and TPG Capital Management this spring that the Canadian drugmaker rejected, according to a source familiar with the matter.

    The offer was made a few weeks before Joseph Papa took over as Valeant's new chief executive in April last week, the source told Reuters.

    The board wants to give Papa time to focus on running the company before thinking about a sale offer, the source said.

    Takeda and private equity firm TPG were ready to offer a substantial premium to Valeant, whose stock had fallen about 65 percent this year up to the close of trade on April 22 as the drugmaker was not just seeking a new head but was also hit by an accounting scandal, the source added.
    TPG and Valeant declined to comment. Takeda did not immediately respond to a request for comment.
    There are currently no talks between the three companies following the bid's rejection, according to the Wall Street Journal, which first reported the news late Thursday.

  • Reply to

    Where is management?

    by kmagnus_w Jun 27, 2016 4:53 PM
    news_to_use news_to_use Jun 27, 2016 7:31 PM Flag

    Management is busy in talks. The company did not lose value - not even in the equity. Only the people who sold or shorted lost value. The shares that didn't sell are still worth the same portion of the company as they were two weeks ago., and the company is still worth at least $45 a share. Leave management alone since they are busy negotiating to get my part of company priced at what it is worth. If you are a frightened crybaby, then go get a fund manager to manage your money and hold your hand - you certainly don't belong here!

  • CETA seeks to establish freer trade between Canada and the EU and includes a section on IP in relation to pharmaceuticals. European negotiators asked Canada to move toward their somewhat stronger standards of pharmaceutical IP protection. Canada met the EU halfway.
    Europe asked Canada to provide brand-name pharmaceutical companies with five years of patent term restoration, whereby they are given back some of the time lost between filing a patent application and gaining market approval for a new drug. Canada agreed to a maximum of two years of patent term restoration, and negotiated an exemption for generic exports. This measure should provide a more encouraging environment for capital investment in health innovation in Canada, while protecting generic manufacturing. The Canadian government also locked in its current data protection period of eight years, but did not accede to Europe's ten-year standard. Finally, Canada committed itself to streamlining its patent litigation system, with attention to the issue of right of appeal for both brand-name and generic pharmaceutical companies in the Federal Court.

  • CETA seeks to establish freer trade between Canada and the EU and includes a section on IP in relation to pharmaceuticals. European negotiators asked Canada to move toward their somewhat stronger standards of pharmaceutical IP protection. Canada met the EU halfway.
    Europe asked Canada to provide brand-name pharmaceutical companies with five years of patent term restoration, whereby they are given back some of the time lost between filing a patent application and gaining market approval for a new drug. Canada agreed to a maximum of two years of patent term restoration, and negotiated an exemption for generic exports. This measure should provide a more encouraging environment for capital investment in health innovation in Canada, while protecting generic manufacturing. The Canadian government also locked in its current data protection period of eight years, but did not accede to Europe's ten-year standard. Finally, Canada committed itself to streamlining its patent litigation system, with attention to the issue of right of appeal for both brand-name and generic pharmaceutical companies in the Federal Court.

  • news_to_use news_to_use Jun 27, 2016 6:36 PM Flag

    I bought 50,000 today.

  • Brexit Boosts Momentum for Canada-EU Trade Pact
    by Bloomberg Video 4:22 mins
    Jun 27 -- The free trade deal between the European Union and Canada is weeks away from being approved in Brussels. But since the U.K. has voted to leave the EU, could the deal be negatively affected? Canada's Minister of International Trade, Chrystia Freeland doesn’t think so. She speaks on The Daily Brief. (Source: Bloomberg)

  • They are not the same commentators though because those short sellers all went broke. I remember one short who lost all his money saying he was going to commit suicide. I'm sure glad to see this company brought in people from TYC because it was much worse there - Tyco had huge debt due the next year and had to immediately fire sale some assets. The funny thing is none of the shorts' predictions came true and TYC got their covenants changed and then refinanced their debt because rates had dropped and everyone was looking for yield (that's what is coming after this Brexit vote - you will see people begging to loan to VRX). I also expect the Fed & central banks to announce up a flood of money within next day or two. Britian already announced a $250 Billion infusion with more coming. It will be fun watching shorts run for cover.

  • Reply to

    Below 17 tomorrow will re assure BK

    by hznpat40 Jun 27, 2016 4:03 PM
    news_to_use news_to_use Jun 27, 2016 6:03 PM Flag

    Yes! stock price only reflects the action of idiots; it has nothing to do with debt or solvency.

  • I bought extremely heavily today. Thank you to all that gave me their shares on the cheap today. In 3 months someone will be crying on this board saying how I cheated them out of their shares by paying too little! LOL

  • news_to_use news_to_use Jun 27, 2016 2:58 PM Flag

    Nonsense article.

AMTD
32.505-0.615(-1.86%)2:47 PMEDT